Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SYRS)

Syros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRS

Newsfile 8 days ago

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Business Wire 8 days ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions

Accesswire November 4, 2024

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Accesswire November 3, 2024

The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations

Accesswire November 2, 2024

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm

Accesswire October 31, 2024

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Business Wire October 31, 2024

The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations

Accesswire October 30, 2024

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders Are Encouraged To Contact The Schall Law Firm

Accesswire October 29, 2024
View More News ››

Opinion & Analysis (NDAQ:SYRS)

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Streetwise Reports December 19, 2019

2017 Small-Cap biotech watchlist update: holding steady in a volatile market

The Life Sciences Report April 21, 2017

2017 Small-Cap Biotech Watchlist: takeaways for investors

The Life Sciences Report January 19, 2017
View More Opinion ››

Bullboard Posts (NDAQ:SYRS)

Bronstein, Gewirtz and Grossman, LLC Is Investigating Syros

NEWS: $SYRS Bronstein, Gewirtz and Grossman, LLC Is Investigating Syros Pharmaceuticals, Inc. (SYRS) And Encourages Investors to...
whytestocks - September 5, 2024

Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharma

Just In: $SYRS Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about...
whytestocks - August 29, 2024

Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein,

NEWS: $SYRS Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Investors to Seek...
whytestocks - August 28, 2024

Bronstein, Gewirtz and Grossman, LLC Announces an Investigat

BREAKING NEWS: $SYRS Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and...
whytestocks - August 26, 2024

Syros (NASDAQ:SYRS) Poised for Potential Breakthrough in Hem

http://beyondspx.com/2024/07/31/syros-nasdaqsyrs-poised-for-potential-breakthrough-in-hematologic-malignancies/
MikeTester - August 2, 2024

Syros to Host Webcast Event on Higher-Risk Myelodysplastic S

News; $SYRS Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New...
whytestocks - June 13, 2024
View more Bullboard ››

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical ...
View More »